Enhance Biotech, Inc., a company developing a portfolio of products focused on lifestyle drugs, announced today that it has sold its opioid Delta receptor compound portfolio to Mount Cook Biosciences Inc., a company formed and funded by Paramount Biosciences, LLC of New York.
PrimeZone
Simplifying Global Compliance
Recommended Products
EU MDR Compliance: A Checklist for Meeting Manufacturing, Safety and Performance Requirements
The FDAnews report EU MDR Compliance can help. Our editors have combed through the regulations, picking out the most minute compliance points and building them into a checklist of 200+ requirements you can use to confirm that you are satisfying all the EU mandates for device manufacturing.
Accelerating Generic Drug Development: The FDA’s New Plan for Increasing Generic Competition
Accelerating Generic Drug Development explains the FDA’s new policy and shows how to navigate the new pathway to approval.
Editor's Picks
Lax Quality Observed at Device Facility in China
The company failed to investigate a customer complaint about a malfunctioning device.
Three Breast Cancer Drugs Pose Risks of Lung Inflammation, FDA Says
Possible symptoms include shortness of breath while resting or during low physical activity, the agency said.
FDAnews Drug Daily Bulletin
ENHANCE BIOTECH ANNOUNCES ASSET SALE AGREEMENT WITH MOUNT COOK BIOSCIENCES
May 23, 2006
